Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
INFINITY PHARMACEUTICALS, INC. Infinity Pharmaceuticals, Inc. Stock price
Equities
INFIQ
US45665G3039
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 0.003 USD | +1.72% | -18.92% | -99.46% | |
| Dec. 04 | North American Morning Briefing : Stock Futures, -2- | DJ |
| Nov. 27 | North American Morning Briefing : Stock Futures -2- | DJ |
Financials (USD)
| Sales 2022 | 2.59M | Sales 2023 * | - | Capitalization | 49.59M |
|---|---|---|---|---|---|
| Net income 2022 | -44M | Net income 2023 * | - | EV / Sales 2022 | 4,70x |
| Net cash position 2022 | 37.4M | Net cash position 2023 * | - | EV / Sales 2023 * | - |
| P/E ratio 2022 | -1,11x | P/E ratio 2023 * | Employees | 30 | |
| Yield 2022 | - | Yield 2023 * |
-
| Free-Float | 97.27% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +1.72% | ||
| 1 week | -18.92% | ||
| Current month | -18.92% | ||
| 1 month | -18.92% | ||
| 3 months | -96.54% | ||
| 6 months | -98.39% | ||
| Current year | -99.46% |
1 week
0.00
0.00
1 month
0.000.01
Current year
0.000.77
1 year
0.000.77
3 years
0.005.98
5 years
0.005.98
10 years
0.0018.25
| Managers | Title | Age | Since |
|---|---|---|---|
Seth Tasker
CEO | Chief Executive Officer | 44 | 2008 |
Jennifer Roberts
PRN | Corporate Officer/Principal | - | 2017 |
Melissa Hackel
PRN | Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Evnin
BRD | Director/Board Member | 82 | 2006 |
Norman Selby
BRD | Director/Board Member | 70 | 2012 |
David W. Beier
BRD | Director/Board Member | 74 | 2018 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | -.--% | - | |
| 0.00% | 281,588 M€ | +19.70% | ||
| 0.00% | 4,253 M€ | +20.05% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-08 | 0.00295 | +1.72% | 72,302 |
| 23-12-07 | 0.0029 | -3.33% | 353,091 |
| 23-12-06 | 0.003 | 0.00% | 135,082 |
| 23-12-05 | 0.003 | 0.00% | 204,467 |
| 23-12-04 | 0.003 | -17.81% | 159,971 |
Delayed Quote OTC Markets, December 08, 2023 at 03:21 pm EST
More quotes
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.
Calendar
2024-03-13
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
D+
| 1st Jan change | Capi. | |
|---|---|---|
| -99.46% | 267 745 $ | |
| +70.40% | 41 313 M $ | |
| +5.07% | 39 289 M $ | |
| -55.28% | 30 625 M $ | |
| -27.34% | 27 758 M $ | |
| +40.26% | 22 431 M $ | |
| -28.45% | 21 339 M $ | |
| +4.49% | 17 693 M $ | |
| -13.10% | 11 356 M $ | |
| -17.58% | 10 803 M $ |
